Clearside Biomedical, Inc.

Clearside Biomedical is a biopharmaceutical company specializing in suprachoroidal drug delivery for sight-threatening diseases of the back of the eye. The company's proprietary SCS® Microinjector® platform enables targeted, in-office suprachoroidal injections that deliver therapeutics to the macula, retina, and choroid with enhanced precision. Clearside has performed over 10,000 clinical injections, establishing deep expertise in commercial execution, clinical development, and regulatory pathways for ocular therapies. XIPERE® (triamcinolone acetonide injectable suspension), approved by the FDA in October 2021, is the first and only FDA-approved suprachoroidal delivery product, indicated for macular edema associated with uveitis. The company is advancing CLS-AX, a small-molecule tyrosine kinase inhibitor candidate in Phase 3 trials targeting the multi-billion dollar wet age-related macular degeneration (wet AMD) market. Clinical programs span six retinal diseases including diabetic macular edema, retinal vein occlusion, and uveitis-related conditions. Clearside partners with pharmaceutical collaborators to expand therapeutic applications of its validated delivery platform.